CD274 and neoplasm: The therapy is applied in various tumors such as esophageal cancer, breast cancer, malignant melanoma, uroepithelial cancer, renal cancer, etc. Taking NSCLC as an example, based on the IMpower 010 study, on March 16, 2022, the National Medical Products Administration (NMPA) approved atezolizumab as adjuvant therapy for patients with stage II-IIIA NSCLC with ≥ 1% tumor cell PD-L1 expression, surgically removed and platinum-based chemotherapy (43).